# Jeito Capital

> Jeito Capital is a VC fund in Paris backing Biotechnology and Health Care. See 45 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Paris, France
- Total investments: 45
- Last investment: Jun 2026
- Lead investor: 67%
- Fund size: $630M
- Last fund: Sep 2021
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/jeito-life
- X (Twitter): https://twitter.com/jeito_life
- Website: https://www.jeito.life/

Jeito Capital is a global investment company that invests in companies in the field of medical innovation. It focuses both on financing ground-breaking medical innovation and promoting positive societal impact. It empowers and supports entrepreneurs through its expert, integrated, multi-talented team.The company was founded in 2018 and is basedin Paris with a presence in Europe and the United States.

## Contacts

5 contacts available for Jeito Capital. Shizune tracks 2 team members at Jeito Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/jeito-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 21 | 47% |
| Health Care | 9 | 20% |
| Therapeutics | 9 | 20% |
| Medical | 6 | 13% |
| Pharmaceutical | 6 | 13% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 12 | 27% |
| Series B | 9 | 20% |
| Series C | 4 | 9% |
| Series D | 3 | 7% |
| Seed | 1 | 2% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 7 | 16% |
| France | 5 | 11% |
| Switzerland | 4 | 9% |
| Belgium | 2 | 4% |
| United Kingdom | 2 | 4% |

8 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Rafaele Tordjman | Founder & CEO | 21 | https://shizune.co/investors/profile/rafaele-tordjman |
| Julien Elric | Senior Principal | 1 | https://shizune.co/investors/profile/julien-elric |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Bionyra | Bionyra Pharma is a clinical-stage biopharmaceutical startup developing next-generation biologics for serious immune-mediated inflammatory diseases. | $165M | Series A | Jun 22, 2026 |  |
| Alveus Therapeutics | Alveus Therapeutics is a clinical-stage biotech company developing therapies for obesity and metabolic diseases. | $197M | Series A | Jan 08, 2026 |  |
| Odyssey Therapeutics | Odyssey Therapeutics is a biotechnology company pioneering the efficient development of next-generation immunomodulators and oncology medicines. Odyssey is making a transformational impact on the field of drug discovery and is accelerating the path to clinical development to drive the creation of more effective precision medicines. | $213M | Series D | Sep 10, 2025 |  |
| ReproNovo | ReproNovo is providing patients all over the world with significant improvement by developing cutting-edge therapeutic solutions for uterine disorders including adenomyosis and for male and female infertility. | $65M | Series A | May 21, 2025 |  |
| Azafaros | Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros. | $147.6M | Series B | May 13, 2025 |  |
| Azafaros | Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros. | $147.6M | Series B | May 13, 2025 |  |
| Augustine Therapeutics | Augustine Therapeutics company is a two drug discovery programs to identify novel generations of selective HDAC6 inhibitors and GABABR1a activators for the treatment of neurological diseases such as Charcot Marie Tooth disease. These new compounds have the potential to protect from nerve degeneration and promote peripheral myelin and axon repair. | $83.9M | Series A | Mar 24, 2025 |  |
| Callio Therapeutics | Callio Therapeutics focuses on developing next-generation, multi-payload antibody-drug conjugates to maximize therapeutic benefits. | $187M | Series A | Mar 03, 2025 |  |
| XyloCor Therapeutics | XyloCor Therapeutics is a bio-pharmaceutical company intended to develop gene therapy for people with advanced coronary artery disease. The company's service focuses on developing gene therapy to stimulate the formation of new coronary blood vessels and serve areas of the heart that are not receiving adequate blood supply, enabling patientswith refractory angina who exhausted pharmacologic options to cure their cardiovascular diseases painlessly and cost effectively. | $67.5M | Series B | Jan 07, 2025 |  |
| Aviceda Therapeutics | Aviceda Therapeutics is a late-stage, pre-clinical biotech company developing drugs for treating glyco-immune diseases. The company focuses on the next generation of immunomodulators by harnessing the power of glycobiology to address the innate immune system and chronic non-resolving inflammation specifically and profoundly. A combination ofcutting-edge technologies and deep biological insights form Aviceda’s engine of transformative product creation.Aviceda uses its cell-based high-throughput screening (HTS) platform to rapidly screen, select, and optimize ligands based on maximum affinity and specificity for each different type of innate immune cell. . The company's products are for eye diseases, fibrosis, neurology, and oncology, for eye diseases like AVD-104, AVD-302, AVD-401 for dry eye, diabetic retinopathy, and retinoblastoma respectively AVD-601, AVD-701 and AVD-801 for oncology, neurology, and fibrosis respectively. | $207.5M | Series C | Jan 07, 2025 |  |

10 of 45 investments shown.

## Co-investors
- [Forbion Capital Partners](https://shizune.co/investors/profile/forbion-capital-partners) — VC Fund, 14 deals together
- [Novo Holdings](https://shizune.co/investors/profile/novo-a-s) — VC Fund, 11 deals together
- [SV Health Investors](https://shizune.co/investors/profile/sv-life-sciences) — VC Fund, 9 deals together
- [UPMC Enterprises](https://shizune.co/investors/profile/upmc-enterprises) — VC Fund, 8 deals together
- [Omega Funds](https://shizune.co/investors/profile/omega-funds) — VC Fund, 7 deals together
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 6 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Jeito Capital invest in?

Jeito Capital invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 45 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Jeito Capital?

Public channels for Jeito Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Jeito Capital?

The team at Jeito Capital includes Rafaele Tordjman (Founder & CEO) and Julien Elric (Senior Principal). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co